LeMaitre Corp (LMAT): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand LeMaitre (LMAT)

LeMaitre Vascular, Inc. (LMAT) dominates narrow niches in vascular surgery through a conservative direct sales model. The price/sales ratio reflects the asset's market valuation, where the 6.70 mark serves as the current indicator. The company implements innovations in collaboration with global clinics, yet faces stringent regulatory pressure in the US and Europe, necessitating strict control over product certification.

Price-to-Revenue Ratio: LeMaitre Vascular (LMAT) for 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for LeMaitre Vascular (LMAT)

- stock quotes and analyst forecast:
Summary company analytics:LeMaitre Vascular Inc
Mass-produced product of lemaitre.com

Comparative asset analysis requires benchmarking market capitalization against actual revenue streams to determine the extent of business overvaluation. The P/S ratio measures the cost of one dollar of revenue, and LeMaitre Vascular, Inc. (LMAT) low dependence on external suppliers enhances the quality of generated sales, making the company's average P/S a reliable indicator of fundamental value and the current phase of the industry cycle.

Competitors of LeMaitre Vascular, Inc.

Market Cap to Sales Volume ISRG|Danaher Corporation - Market Cap to Revenue|P/S Multiple Becton Dickinson & Company BDX|STE - Price-to-Revenue Ratio|West Pharmaceutical Services (WST) - Market Cap to Revenue|BAX: P/S Multiple|Market Cap to Revenue Masimo|STVN (stevanatogroup.com) - P/S Multiple|Market Cap to Revenue Ratio TFX (Teleflex Incorporated)|Price-to-Revenue Ratio Merit Medical (MMSI)|Envista - Market Cap to Revenue Ratio|ICU Medical, Inc. - Market Cap to Revenue|Market Cap to Sales Volume XRAY (Dentsply Sirona Inc)|ATRC - Price-to-Revenue Ratio|Price-to-Revenue Coefficient STAAR Surgical Co STAA|NAGE: P/S Multiple|Price-to-Sales Ratio ZIMV (ZimVie Inc.)|Price-to-Revenue Ratio AngioDynamics Corp|Price to Sales Cerus Corp. CERS|Price-to-Revenue Ratio Teknova (TKNO)|Monogram Orthopedics Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Sharps Technology, Inc. STSS|P/S Multiple InfuSystem Holdings INFU|UTMD: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KRMD (KORU Medical)|NYXH: P/S Multiple|MBOT (Microbot Medical, Inc) - Price-to-Revenue Ratio|Market Cap to Revenue PDEX|ZTEK: Market Capitalization-to-Revenue Ratio|P/S Multiple ELUT|Milestone Scientific Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio NEXGEL, Inc. NXGL|Retractable Tech - Price-to-Revenue Ratio|harvardbioscience.com - P/S Multiple|FEMY (Femasys Inc.) - Market Cap to Revenue Ratio|MHUA: P/S Multiple|Predictive Oncology Corp - Market Capitalization-to-Revenue Ratio|CJMB (Callan JMB) - P/S Multiple|Price to Sales Atrion Corporation Inc. ATRI|P/S Multiple NURO